Hood River Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $32.4M | Sell |
257,538
-79,626
| -24% | -$10M | 0.45% | 78 |
|
|
2025
Q1 | $37.3M | Sell |
337,164
-17,894
| -5% | -$1.98M | 0.64% | 66 |
|
|
2024
Q4 | $48.5M | Buy |
355,058
+91,848
| +35% | +$12.5M | 0.72% | 55 |
|
|
2024
Q3 | $30.3M | Buy |
263,210
+19,313
| +8% | +$2.23M | 0.49% | 76 |
|
|
2024
Q2 | $33.6M | Buy |
243,897
+15,899
| +7% | +$2.19M | 0.7% | 55 |
|
|
2024
Q1 | $31.4M | Buy |
227,998
+15,608
| +7% | +$2.15M | 0.7% | 58 |
|
|
2023
Q4 | $28M | Buy |
212,390
+1,093
| +0.5% | +$144K | 0.77% | 54 |
|
|
2023
Q3 | $23.8M | Sell |
211,297
-1,793
| -0.8% | -$202K | 0.76% | 55 |
|
|
2023
Q2 | $20.1M | Buy |
213,090
+7,046
| +3% | +$664K | 0.6% | 65 |
|
|
2023
Q1 | $20.9M | Buy |
206,044
+6,356
| +3% | +$643K | 0.68% | 56 |
|
|
2022
Q4 | $23.9M | Buy |
199,688
+5,282
| +3% | +$631K | 0.87% | 48 |
|
|
2022
Q3 | $20.6M | Buy |
194,406
+3,678
| +2% | +$391K | 0.79% | 47 |
|
|
2022
Q2 | $18.6M | Buy |
190,728
+10,171
| +6% | +$991K | 0.74% | 55 |
|
|
2022
Q1 | $16.9M | Buy |
180,557
+3,689
| +2% | +$346K | 0.56% | 59 |
|
|
2021
Q4 | $15.1M | Sell |
176,868
-1,849
| -1% | -$157K | 0.45% | 70 |
|
|
2021
Q3 | $17.1M | Buy |
+178,717
| New | +$17.1M | 0.53% | 65 |
|
|
2020
Q2 | – | Sell |
-110,040
| Closed | -$9.52M | – | 114 |
|
|
2020
Q1 | $9.52M | Buy |
+110,040
| New | +$9.52M | 0.54% | 63 |
|
|
2017
Q2 | – | Sell |
-109,314
| Closed | -$4.73M | – | 94 |
|
|
2017
Q1 | $4.73M | Sell |
109,314
-96,015
| -47% | -$4.16M | 0.36% | 85 |
|
|
2016
Q4 | $7.95M | Buy |
205,329
+107,257
| +109% | +$4.15M | 0.69% | 63 |
|
|
2016
Q3 | $4.97M | Sell |
98,072
-40,935
| -29% | -$2.07M | 0.51% | 72 |
|
|
2016
Q2 | $6.32M | Buy |
139,007
+3,452
| +3% | +$157K | 0.85% | 52 |
|
|
2016
Q1 | $5.36M | Buy |
+135,555
| New | +$5.36M | 0.72% | 62 |
|